OCGC earns more than 3x investment from Affinium sale
Ontario Capital Growth Corp (OCGC) has received more than three times its investment in Affinium Pharmaceuticals Inc following the latter's sale to Debiopharm Group. OCGC said it saw $19 million from the sale of Affinium, a Canadian biopharmaceutical company focused on the development of novel anti-infective medicines. The acquisition deal was first announced by Switzerland's Debiopharm in February 2014 and has since closed. Canadian life sciences venture capital firm Genesys Capital assumed a leading role in funding Affinium since its inception in 2000. Its other backers included Forward Ventures Partners and SV Life Science Advisors.
7 April 2015•3 mins read
